Market Newsdesk

 Wolters Kluwer releases its 2020 Annual Report
Agenda and convocation notice AGM available online

March 10, 2021 –
Wolters Kluwer, a global provider of professional information, software solutions, and services, today released its 2020
Annual Report and 2020 Environmental, Social, and Governance Data Overview
. The Financial Statements for 2020, as included in the 2020 Annual Report,
will be proposed for adoption
at t
he Annual General Meeting of Shareholders (AGM) on April 22, 2021.

The agenda with explanatory notes, and the convocation notice for the AGM are now available at www.wolterskluwer.com/agm. The agenda for the AGM includes the proposal to distribute a total dividend over the 2020 financial year of €1.36 per ordinary share. If approved, this will result in a final dividend of €0.89 per ordinary share. Furthermore, the proposals to re-appoint Frans Cremers and Ann Ziegler as members of the Supervisory Board and Kevin Entricken as member of the Executive Board are on the agenda. The proposal to adopt the amended remuneration policy for the members of the Executive Board is also on the agenda.

The information for the AGM includes an update of issued share capital on which votes can be cast at the meeting. The AGM will be held virtually, through a webcast, on April 22, 2021.

The 2020 Annual Report, with integrated selected sustainability information, and the 2020 Environmental, Social, and Governance Data Overview, are available in PDF on www.wolterskluwer.com/annual-report.

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the healthcare; tax and accounting; governance, risk, and compliance; and legal and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.

Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.

Financial Calendar

March 10, 2021                Publication of Annual Report
April 22, 2021                   Annual General Meeting of Shareholders
April 26, 2021                   Ex-dividend date: 2020 final dividend
April 27, 2021                   Record date: 2020 final dividend
May 5, 2021                     First-Quarter 2021 Trading Update
May 19, 2021                   Payment date: 2020 final dividend ordinary shares
May 26, 2021                   Payment date: 2020 final dividend ADRs
August 4, 2021                 Half-Year 2021 Results
August 31, 2021               Ex-dividend date: 2021 interim dividend
September 1, 2021          Record date: 2021 interim dividend
September 23, 2021        Payment date: 2021 interim dividend ordinary shares
September 30, 2021        Payment date: 2021 interim dividend ADRs
November 3, 2021           Nine-Month 2021 Trading Update
February 23, 2022           Full-Year 2021 Results

Media                                                                                      Investors/Analysts

Gerbert van Genderen Stort                                                    Meg Geldens
Global Branding & Communications                                        Investor Relations
t + 31 (0)172 641 230                                                               t + 31 (0)172 641 407      
[email protected]                                                        [email protected]

Forward-looking statements and other important legal information

This report contains forward-looking statements. These statements may be identified by words such as “expect”, “should”, “could”, “shall” and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer’s businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Elements of this press release contain or may contain inside information about Wolters Kluwer within the meaning of Article 7(1) of the Market Abuse Regulation (596/2014/EU).

Attachment

• 2021.03.10 Wolters Kluwer Releases its 2020 Annual Report

Pratteln, Switzerland, March 10, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 480,708 treasury shares. The number of shares recorded in the commercial register has been increased to 21,510,404 shares.

On March 9, 2021, and as announced when calling the extraordinary general meeting of shareholders scheduled for March 18, 2021, 480,708 shares were issued out of the existing authorized capital as treasury shares. Santhera expects to use these shares for purposes of its financing arrangements. The new shares will be listed as per March 10, 2021.

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera has an exclusive license for all indications worldwide to vamorolone, a first-in-class dissociative steroid with novel mode of action, currently investigated in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases, as well as an exploratory gene therapy approach targeting congenital muscular dystrophies. Santhera out-licensed ex-North American rights to its first approved product, Raxone® (idebenone), for the treatment of Leber’s hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit www.santhera.com. 

Raxone^® is a trademark of Santhera Pharmaceuticals.

For further information please contact:


[email protected]
or
Eva Kalias, Head External Communications
Phone: +41 79 875 27 80
[email protected]

Disclaimer / Forward-looking statements

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #

Attachment

• 2021 03 10_CapIncreaseFinancings_e_finalx

•      The application includes robust data from the Phase 3 registration program, which demonstrated efficacy of daridorexant on objective and subjective sleep parameters, and an improvement in daytime functioning, while maintaining a favorable safety profile

Allschwil, Switzerland – March 10, 2021

Idorsia Ltd (SIX: IDIA) today announced that the US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for review of Idorsia’s investigational dual orexin receptor antagonist, daridorexant, for the treatment of adult patients with insomnia.

Insomnia is a common problem with approximately 25 million adults in the US who meet the diagnostic criteria. Insomnia, a condition of overactive wake signaling, is defined as a combination of dissatisfaction with sleep and a significant negative impact on daytime functioning. Dissatisfaction with sleep refers to the difficulty to initiate and/or maintain sleep on at least three nights per week for at least three months, despite adequate opportunity to sleep.

Jean-Paul Clozel, MD and Chief Executive Officer of Idorsia commented:

“I’m very happy that this first regulatory hurdle is behind us. This was a huge NDA and the team has done an excellent job in preparing the dossier, on which the FDA can judge the properties and merits of daridorexant. We now stand-by to work with the FDA to answer any questions that might arise concerning the effect of daridorexant on sleep, daytime functioning and its safety profile.”

The NDA includes data from a comprehensive clinical and non-clinical development program. In the Phase 3 registration program, daridorexant showed statistically significant and clinically meaningful improvements in sleep during the night and, for the first time for an insomnia treatment, in daytime functioning, which were sustained over time.

The Phase 3 program provided a deep understanding of the safety and tolerability profile of daridorexant. Adverse reactions reported with a frequency of ≥ 2% in daridorexant-treated patients and greater (≥ 1%) than in placebo-treated patients in 3-month efficacy trials were headache, somnolence, fatigue, dizziness, and nausea. The incidence of somnolence was low and did not increase with daridorexant 50 mg compared to placebo. Patients reported no next-morning sleepiness compared to placebo as assessed by the morning visual analogue scale (VAS).

These results make daridorexant the first sleep medication to demonstrate an improvement in sleep and daytime functioning, as measured by a newly developed and validated instrument, while keeping a favorable safety profile in adult and elderly patients.

In April and July of 2020, Idorsia reported positive results in each of the two pivotal Phase 3 studies of daridorexant in patients with insomnia. More details and commentary can be found in the dedicated press releases (first study release), (second study release) and the investor webcasts (first study webcast), (second study webcast) which are available for replay on Idorsia’s corporate website: www.idorsia.com

The NDA was submitted to the US FDA on January 8, 2021 and the MAA to the European Union EMA on March 2, 2021. Should approval be received, the company anticipates launch in the US in the first half of 2022.

Notes to the editor

About the orexin system

Wake and sleep signaling is regulated by intricate neural circuitry in the brain. One key component of this process is the orexin system, which helps promote wakefulness. There are two forms of orexin neuropeptides – small protein-like molecules used by nerve cells (neurons) to communicate with each other in the brain – orexin A and orexin B. Orexin promotes wakefulness through its receptors OX1R and OX2R. Together, these neuropeptides and receptors make up the orexin system. The orexin system stimulates targeted neurons in the wake system – leading to the release of several chemicals (dopamine, serotonin, histamine, acetylcholine, norepinephrine) which promote wakefulness. Under normal circumstances, orexin levels rise throughout the day as wakefulness is promoted and then fall at night. Overactivity of the wake system is an important driver of insomnia.

Dual orexin receptor antagonists (DORAs) offer an entirely different approach to treating insomnia than previous drug classes: by blocking the activity of orexin, they turn down overactive wakefulness, in contrast to insomnia treatments which act via general CNS sedation. DORAs specifically target the orexin system by competitively binding with both receptors, thereby reversibly blocking the activity of orexin. Blocking orexin receptors reduces the downstream activity of the wake-promoting neurotransmitters that are overactive in insomnia. As a result, orexin receptor antagonism targets the fundamental mechanism of insomnia.

About daridorexant

Daridorexant is a dual orexin receptor antagonist (DORA) designed and developed for the treatment of insomnia. Daridorexant reduces overactive wakefulness associated with insomnia by blocking the activity of orexin. Idorsia’s research team has designed daridorexant to have a rapid onset of effect and a duration of action sufficient to cover the night but short enough to avoid any negative next-morning residual activity at optimally effective doses.

About the registration program

The Phase 3 registration program comprised two three-month studies, together with a long-term double-blind extension study. Both pivotal studies are complete, having enrolled around 1,850 patients with insomnia at over 160 sites across 18 countries. As insomnia often presents later in life, and elderly patients are more susceptible to fragmented sleep, early awakening and daytime sleepiness, around 40% of the recruited population was aged 65 years or older. The placebo-controlled studies investigated the effects of three doses of daridorexant (10 mg, 25 mg, and 50 mg) on sleep and daytime functioning parameters, objectively in a sleep lab by polysomnography and subjectively with a daily patient diary at home. The impact of insomnia on patients’ daytime functioning was measured daily using the sleepiness domain score from the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) – a patient-reported outcome (PRO) instrument validated according to FDA industry guidance.

More than 800 patients continued treatment in the ongoing 40‑week extension study, which will measure the effects of all three doses vs placebo, generating data for long-term treatment of insomnia.

The Phase 3 registration program demonstrated statistically significant and clinically meaningful improvements in sleep and daytime functioning which were sustained over time. The results showed efficacy during the night and the day, in respect of sleep maintenance, sleep onset, total sleep time and daytime functioning. The nighttime symptoms were improved while preserving the proportions of sleep stages.

The highest (50 mg) dose was the most effective, followed by 25 mg, while the 10 mg dose had only a marginal effect. A key consideration in the treatment of insomnia is the reversal of daytime functioning impairment associated with sleep difficulties – altered mood, cognition, and tiredness. To date, no insomnia studies have reported on the effects of pharmacological intervention on daytime functioning using an adequately developed and validated PRO instrument. At 50 mg, daridorexant produced consistent and meaningful improvements in scores for daytime functioning across all IDSIQ domains. Patients on daridorexant felt more energetic and less sleepy, and reported better alertness, cognition and mood.

Daridorexant was well tolerated and had a favorable safety profile in adult and elderly patients. Adverse reactions reported with a frequency of ≥ 2% in daridorexant-treated patients and greater (≥ 1%) than in placebo-treated patients in 3-month efficacy trials were headache, somnolence, fatigue, dizziness, and nausea. There was no excess of morning sleepiness, as assessed by the morning visual analogue scale (VAS), even at 50 mg. The incidence of somnolence was low and did not increase with daridorexant 50 mg compared to placebo. The incidence of adverse events of special interest, considering the potential association of orexin deficiency with narcolepsy, was low, with isolated cases of sleep paralysis or hallucinations in the daridorexant treatment groups.

About insomnia

Insomnia is defined as a combination of dissatisfaction with sleep and a significant negative impact on daytime functioning. Dissatisfaction with sleep refers to the difficulty to initiate and/or maintain sleep on at least three nights per week for at least three months, despite adequate opportunity to sleep.

Insomnia is a condition of overactive wake signaling and studies have shown that areas of the brain associated with wakefulness remain more active during sleep in patients with insomnia.

Insomnia is a common problem with a prevalence of approximately 10%. On this basis, and assuming a US adult population of around 250 million, there are approximately 25 million adults in the US who suffer from insomnia.

Insomnia as a disorder is quite different from a brief period of poor sleep, and it can take its toll on both physical and mental health. It is a persistent condition with a negative impact on daytime functioning. Idorsia’s research has shown that poor-quality sleep can affect many aspects of daily life, including the ability to concentrate, mood, and energy levels.

The goal of treatments for insomnia is to improve sleep quality and quantity, as well as daytime functioning, while avoiding adverse events and next-morning residual effects. Current recommended treatment of insomnia includes sleep hygiene recommendations, cognitive behavioral therapy and pharmacotherapy.

Key literature

• Hudgens S, et al. Patient. 2020;14(2): 249-268.
• Dauvilliers, Y., et al. Ann Neurol. 2020;87(3): 347-356.
• Muehlan, C., et al. J Clin Psychopharmacol. 2020;40(2): 157-166.
• Muehlan, C., et al. J Psychopharmacol. 2020;34(3): 326-335.
• Wardle-Pinkston S, et al. Sleep Med Rev.2019;48:101205.
• Altinas HK, et al. Int J Nurs Pract. 2019;25(5):e12766.
• Boof, M. L., et al. Eur J Clin Pharmacol. 2019;75(2): 195-205.
• Muehlan, C., et al. Curr Drug Metab. 2019;20(4): 254-265.
• Muehlan, C., et al. Eur Neuropsychopharmacol. 2019;29(7): 847-857.
• Muehlan, C., et al. Clin Pharmacol Ther. 2018;104(5): 1022-1029.
• Wang C, et al. Front Mol Neurosci. 2018;11:220.
• Olfson M, et al. J Clin Psychiatry. 2018;79(5):17m12020.
• Purves D, et al. Chapter 28. In: Neuroscience. 6th ed. Sunderland, MA; Oxford University Press; 2018.
• Treiber A, et al. J Pharmacol Exp Ther. 2017;362(3):489-503.
• Kryger M, et al, eds. Principles and Practice of Sleep Medicine. 6th ed. Philadelphia, PA: Elsevier; 2017.
• Levenson JC, et al. Chest. 2015;147(4):1179-1192.
• The Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM–5; American Psychiatric Association, 2013).
• Buysse DJ, et al. Drug Discov Today Dis Models. 2011;8(4):129-137.
• Walsh JK, et al. Sleep. 2011;34(8):997-1101.
• Brisbare-Roch, C., et al. Nat Med. 2007;13(2): 150-5.
• Nofzinger EA, et al. Am J Psychiatry. 2004;161(11):2126-2128.
• Ohayon, Sleep Medicine Reviews 6(2002)

About Idorsia

Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet – the ideal constellation to translate R&D efforts into business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 900 highly qualified specialists dedicated to realizing our ambitious targets.

For further information, please contact

Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
[email protected]
[email protected]
www.idorsia.com

The above information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Attachment

• Press Release PDF

GHENT, Belgium, March 10, 2021 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, will announce its full year results ended 31 December 2020 on Wednesday, 17 March 2021.

The management team will host a conference call with live webcast at 02:00 pm CET / 08:00 am EST on the day of the results.

The webcast can be accessed by registering via the investors homepage of the Sequana Medical website or by clicking here. To participate in the Q&A, please click here to register. Once registered, you will receive dial-in numbers and a confirmation code. The webcast and conference call will be conducted in English and a replay will be available on the Company’s website shortly thereafter.

For more information, please contact:

Sequana Medical 
Lies Vanneste
Director Investor Relations
Tel: +32 498 05 35 79
Email: [email protected]

LifeSci Advisors 
Chris Maggos
Tel: +41 79 367 6254
Email: [email protected]   

About Sequana Medical

Sequana Medical is a commercial stage medical device company developing the alfapump^® platform for the treatment of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. Fluid overload is a frequent complication of many large diseases including advanced liver disease driven by NASH (non-alcoholic steatohepatitis)-related cirrhosis and heart failure, with diuretic resistance being widespread. The U.S. market for the alfapump resulting from NASH-related cirrhosis is forecast to exceed €3 billion annually within the next 10-20 years. The heart failure market for the alfapump DSR (Direct Sodium Removal) is estimated to be over €5 billion annually in the U.S. and EU5 by 2026. Both indications leverage Sequana Medical’s alfapump, a unique, fully implanted wireless device that automatically pumps fluid from the abdomen into the bladder, where it is naturally eliminated through urination.

In the U.S., the company’s key growth market, the alfapump has been granted breakthrough device designation by the FDA for recurrent or refractory ascites due to liver cirrhosis. Interim data from the ongoing North American pivotal study (POSEIDON) showed positive outcomes against all primary endpoints of the study. This study is intended to support a future marketing application of the alfapump in the U.S. and Canada. In Europe, the alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and is included in key clinical practice guidelines. Over 850 alfapump systems have been implanted to date. Building on its proven alfapump platform, Sequana Medical is developing the alfapump DSR^®, a breakthrough, proprietary approach to fluid overload due to heart failure. Clinical proof-of-concept was achieved in a first-in-human single dose DSR^® study and further supported by strong interim safety and efficacy results from the ongoing repeated dose alfapump DSR study (RED DESERT) in heart failure patients.

Sequana Medical is headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com.

Important Regulatory Disclaimers

The 

alfa

pump^® system is not currently approved in the United States or Canada. In the United States and Canada, the 

alfa

pump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see 

www.poseidonstudy.com

. The DSR^® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. The DSR^® therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR^® therapy and ongoing investigations with the 

alfa

pump^® system in Europe, the United States or Canada. DSR^® and

alfa

pump DSR^® are registered trademarks in Benelux.

Forward-looking statements

This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

Note:


alfa

pump^® is a registered trademark. DSR^® and

alfa

pump DSR^® are registered trademarks in the Benelux.

• New data on the role of osteoimmunology in bone formation at BritSpine Meeting
  
• Investor presentation at BioCapital Europe

SCHLIEREN (ZURICH), Switzerland, March 10, 2021 (GLOBE NEWSWIRE) — Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced that the company will present at two major European conferences in March, both to be held virtually.

Joost de Bruijn, Chief Executive Officer, and Michael Grau, Chief Financial Officer, will participate in the 18th edition of BioCapital Europe, the premier life investment venue organized by LSP on March 11. Joost de Bruijn will deliver a corporate presentation at 11.30 CET, and be available, with Michael Grau, for 1×1 meetings with investors. For more info about this event, please visit the meeting website: https://www.biocapitaleurope.com

Kuros will also present real-world clinical data and research on the role of osteoimmunology in bone formation in two presentations at the 11th BritSpine conference, taking place March 10-12. Lukas A. van Dijk will present research that demonstrates the following properties after treatment with Kuros’ MagnetOs:

• Direct upregulation of pro-healing, anti-inflammatory immune cells by the unique needle-shaped surface of Kuros’ MagnetOs™ advanced bone graft.
• Increased vascularization by epithelial cells grown in the same pro-healing microenvironment compared to the market-leading synthetic bone graft, Vitoss®.

In addition, Dr Kornelis Poelstra MD PhD of the Robotic Spine Institute of Las Vegas will be presenting his findings from a series of patients treated using MagnetOs in his clinical practice.

Details for the presentations:

• Calcium phosphates with submicron topography enhance human macrophage M2 polarization (In Vitro). Lukas A. van Dijk. March 10, at 10AM GMT (11AM CET)
• Cervical- and lumbar spinal fusion through submicron surface topography – Real life clinical data. Kornelis Poelstra. March 10, at 12.30PM GMT (1.30PM CET)

For more info about BritSpine 2021, please visit the https://www.ukssb.com/britspine2021.

MagnetOs bone graft is supported by a growing set of preclinical data demonstrating equivalence to the current gold standard, autograft, with over three years of clinical experience since its first use in the UK in May 2017.

For further information, please contact:

About Kuros Biosciences AG


Kuros Biosciences is a leader in next generation synthetic bone graft technologies for targeted and controlled bone healing. Kuros’s bone graft substitute, MagnetOs, is commercialized in the U.S. and UK for use in posterolateral spinal fusions. Kuros’s lead product in development, Fibrin PTH, a drug-biologic combination for spinal interbody fusion, has started a phase 2 clinical trial in the U.S. Kuros is located in Schlieren (Zurich), Switzerland, Bilthoven, The Netherlands and Burlington (MA), U.S. The Company is listed according to the International Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit

www.kurosbio.com

for additional information on Kuros, its science and product pipeline.

About MagnetOs bone graft


MagnetOs bone graft has an advanced submicron surface topography that leads to the formation of bone in spinal fusion defects rather than scar tissue. In preclinical models, MagnetOs preferentially directs the body’s early wound healing response toward the bone-forming pathway, an effect that is so potent that bone can be formed even in soft tissues without the need for added cells or growth factors. This ground-breaking research led to Kuros attaining an osteoinductive claim for MagnetOs in Europe. Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans. MagnetOs is not cleared by FDA as an osteoinductive bone graft.

US indications statement


MagnetOs is an implant intended to fill bony voids or gaps of the skeletal system, i.e., posterolateral spine. MagnetOs must be used with autograft as a bone graft extender in the posterolateral spine. These osseous defects may be surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure.

EU indications statement


MagnetOs is intended for use as bone void filler for voids and gaps that are not intrinsic to the stability of the bony structure. MagnetOs is indicated for use in the treatment of surgically created osseous defects or osseous defects resulting from traumatic injury to the bone. MagnetOs is intended to be packed into bony voids or gaps of the skeletal system (i.e. extremities, spine, cranial, mandible, maxilla and pelvis) and may be combined with autogenous bone. MagnetOs should not be used to treat large defects that in the surgeon’s opinion would fail to heal spontaneously. In load bearing situations, MagnetOs is to be used in conjunction with internal or external fixation devices.

Forward Looking Statements


This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

South Jordan, UT, March 10, 2021 (GLOBE NEWSWIRE) — CallTower announced today that TMC, a global, integrated media company, has named CallTower’s Native Microsoft Teams Direct Routing solution as a recipient of a 2021 INTERNET TELEPHONY Product of the Year Award.   

CallTower was the first solution provider to deliver an integrated Office 365 Native Microsoft Teams experience with global calling plans, empowered by a 24/7/365 US-based client services team – ensuring a personalized implementation, adoption, training and support strategy. As a Microsoft Gold Partner, CallTower enables customers to bring their current voice services into the Microsoft Cloud through Microsoft Teams Direct Routing. CallTower delivers key Microsoft Teams unified communication as a service (UCaaS) features and functionality which are unavailable through other providers. CallTower is also the only voice provider delivering Direct Routing in GCC High through our Session Border Control (SBCs) for Security to support Microsoft 365 GCC High for government contractors that work with the Department of Defense. 

“I am honored to recognize CallTower with a 2021 Product of the Year Award for its commitment to excellence and innovation,” said Rich Tehrani, CEO, TMC. “In the opinion of our judges and editorial team, CallTower has proven to be among the best communications and technology solutions available on the market. I look forward to continued leadership from CallTower. 

“We are thrilled to receive this coveted award from TMC for our robust Native Microsoft Teams Direct Routing solution,” added CallTower Chief Revenue Officer William Rubio. “Our Native Microsoft Teams solution empowers customers with additional UCaaS features and integrations to boost productivity and efficiency while saving money in the process,” 

The winners of the 2021 INTERNET TELEPHONY Product of the Year will be featured in INTERNET TELEPHONY magazine online and on TMCnet. 

About 
CallTower 

Since its inception in 2002, CallTower has become a leading provider of cloud-based, enterprise-class Unified Communications as a Service (UCaaS) and Contact Center as a Service (CCaaS) solutions for growing organizations worldwide. CallTower provides, integrates, and supports industry-leading, cloud-based, UCaaS and CCaaS solutions, including Native Microsoft® Teams Direct Routing, Microsoft® Office 365, Cisco® HCS, Cisco® Webex, Enterprise Hosted Skype for Business, CT Cloud Voice, CT Cloud Boost, CT Cloud Meeting powered by Zoom and Cloud Contact Center for business customers. 

About 
INTERNET TELEPHONY
 Magazine 

INTERNET TELEPHONY has been the IP Communications Authority since 1998™. Beginning with the first issue, INTERNET TELEPHONY magazine has been providing unbiased views of the complicated converged communications space.   

About 
TMC 

Through education, industry news, live events and social influence, global buyers rely on TMC’s content-driven marketplaces to make purchase decisions and navigate markets. As a result, leading technology vendors turn to TMC for unparalleled branding, thought leadership and lead generation opportunities. Our in-person and online events deliver unmatched visibility and sales prospects for all participants. Through our custom lead generation programs, we provide clients with an ongoing stream of leads that turn into sales opportunities and build databases. Additionally, we bolster brand reputations with the millions of impressions from display advertising on our news sites and newsletters. Making TMC a 360-degree marketing solution, we offer comprehensive event and road show management services and custom content creation with expertly ghost-crafted blogs, press releases, articles and marketing collateral to help with SEO, branding, and overall marketing efforts.  

For more information contact [email protected].

Attachment

• 2021-IT-POTY